Keywords: Protalix, Taliglucerase, Gaucher disease, Pfizer, USA, FDA

Protalix submits CRL reply to FDA on Gaucher drug taliglucerase; reports new trial data

Article | 02 August 2011

Print This

USA-based Protalix BioTherapeutics (NYSE-AMEX: PLX) says it has submitted its reply to the Complete Response Letter issued by the Food ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in